ATP13A1

Across TCGA pan-cancer cohorts, ATP13A1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP13A1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ATP13A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP13A1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

OV, GBM, and HNSC are the cancer types where ATP13A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.457	0.896	.014	16	view →
GBM	OS	Tertile	All	0.986	0.666	.003	12	view →
HNSC	DFS	Median	All	0.698	1.000	.020	9	view →
LUAD	DFS	Median	All	0.957	0.841	.008	6	view →
CCRCC	OS	Tertile	All	0.659	1.000	.019	1	view →
LSCC	OS	Tertile	II,III,IV	0.580	0.864	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP13A1–OV (DFS)

Open the OV breakdown →